Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVRA vs ALEVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Onchocerciasis (river blindness),Strongyloidiasis (threadworm infection),Scabies (off-label, FDA-approved for scabies in certain contexts; also used off-label for head lice, pediculosis, and various parasitic infections)
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Intravenous 500 mg every 6 hours.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in elderly patients.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Primarily metabolized by CYP3A4 in the liver; also a substrate for P-glycoprotein (P-gp) transporter.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; fecal/biliary excretion is the primary route (60-70% as metabolites, primarily unchanged drug via bile).
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Approximately 85-90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
>99% bound to albumin; saturable at high concentrations.
0.6-0.8 L/kg, indicating distribution into total body water with some extravascular binding; increased in heart failure or severe hepatic disease.
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Oral: 70-80% (extensive first-pass metabolism reduces from 90% absorbed); Intravenous: 100%.
Oral: ~95%; immediate-release formulation.
GFR >60 m L/min: 500 mg q6h; GFR 30-60: 250 mg q6h; GFR 15-30: 250 mg q12h; GFR <15: 250 mg q24h.
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg q6h; Child-Pugh C: 250 mg q12h.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Same as adult; monitor renal function and adjust per GFR.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
None.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Potential for severe adverse reactions (Mazzotti reaction) in onchocerciasis patients; neurotoxicity (especially in elderly or patients with high drug levels); avoid use in patients with impaired hepatic function; caution with concomitant use of CNS depressants; not recommended in pregnancy (Category C).
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Hypersensitivity to ivermectin or any component of the formulation; not for use in pediatric patients weighing less than 15 kg for scabies treatment (due to risk of neurotoxicity).
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
No food interactions with IVRA technique; however, lidocaine administration may be affected by grapefruit juice (inhibits metabolism) — avoid grapefruit juice before procedure.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal nephrotoxicity, oligohydramnios, and premature ductus arteriosus closure.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Excreted into breast milk in low amounts; M/P ratio 0.3. Avoid use due to potential adverse effects in nursing infants (renal impairment, bleeding).
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
No dose adjustment is recommended as IVRA is contraindicated. In case of inadvertent use in pregnancy, discontinue immediately.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
IVRA (intravenous regional anesthesia) is not a drug but a technique. For Bier block using lidocaine, use 0.5% preservative-free lidocaine, 3 mg/kg for upper extremity. Avoid in patients with sickle cell disease or severe hypertension. Monitor for tourniquet pain after 30 minutes; deflate tourniquet gradually to prevent systemic toxicity.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
You will receive local anesthetic injected into a vein in your arm after a tourniquet is applied.,The tourniquet will be kept inflated during the procedure to keep the medication in the arm.,You may feel a burning sensation when the medication is injected, which is normal.,Do not remove the tourniquet yourself; it will be deflated slowly by the doctor to prevent side effects.,Report any chest discomfort, ringing in ears, or metallic taste immediately.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVRA vs ALEVE, answered by our medical review team.
IVRA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.. ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVRA and ALEVE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVRA is: Intravenous 500 mg every 6 hours.. The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVRA and ALEVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVRA is classified as Category C. IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal n. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.